Meeting
2015 ASCO Annual Meeting
Overall survival analysis from a randomized phase II study of axitinib with or without dose titration for first-line metastatic renal cell carcinoma.
Authors
Brian I. Rini
Cleveland Clinic Taussig Cancer Institute, Cleveland, OH
Brian I. Rini , Yoshihiko Tomita , Bohuslav Melichar , Takeshi Ueda , Viktor Grünwald , Mayer N. Fishman , Hirotsugu Uemura , Mototsugu Oya , A H. Bair , Glen Andrews , Dmitri Pavlov , Eric Jonasch
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Genitourinary (Nonprostate) Cancer
Track
Genitourinary Cancer
Sub Track
Kidney Cancer
Clinical Trial Registration Number
NCT00835978
Citation
J Clin Oncol 33, 2015 (suppl; abstr 4545)
DOI
10.1200/jco.2015.33.15_suppl.4545
Abstract #
4545
Poster Bd #
218
Abstract Disclosures
Similar Posters
Poster
2013 Genitourinary Cancers Symposium
Axitinib with or without dose titration for first-line metastatic renal cell carcinoma (mRCC): Unblinded results from a randomized phase II study.
First Author: Brian I. Rini
Poster
2019 Genitourinary Cancers Symposium
Axitinib versus sunitinib as first-line therapies for metastatic renal cell carcinoma: A multicenter retrospective analysis.
First Author: Shingo Hatakeyama
Poster
2018 Genitourinary Cancers Symposium
A FavorAx study of axitinib in favorable risk patients with metastatic renal cell carcinoma.
First Author: Ilya Tsimafeyeu
Poster
2017 Genitourinary Cancers Symposium
Patients with metastatic renal cell carcinoma who have benefit from axitinib dose titration: Analysis from a randomized, double-blind, axitinib dose titration phase II study.
First Author: Yoshihiko Tomita